Long-Term Clinical Practice Experience with Cinacalcet for Treatment of Hypercalcemic Hyperparathyroidism after Kidney Transplantation

Figure 5

Markers of bone formation and resorption in kidney transplant recipients treated with cinacalcet for hypercalcemic hyperparathyroidism. Variations of (a) bone specific alkaline phosphatase, (b) osteocalcin, and (c) C-telopeptide before and after initiation of cinacalcet () are plotted over time. Starting point of the pretreatment period is the date when the patients initially presented with hypercalcemia following transplantation. For both pre- and posttreatment period, quarterly median values were obtained for each patient by summarizing all repeated measurements over a three-month period starting from . Data of all patients are presented as medians and interquartile ranges. The shaded area depicts the reference range.

(a)

(b)

(c)